WO2023072913 - BENZO[H]QUINAZOLINE-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER
National phase entry:
Publication Number
WO/2023/072913
Publication Date
04.05.2023
International Application No.
PCT/EP2022/079738
International Filing Date
25.10.2022
Title **
[English]
BENZO[H]QUINAZOLINE-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER
[French]
DÉRIVÉS DE BENZO[H]QUINAZOLINE-4-AMINE POUR TRAITER LE CANCER
Applicants **
REDONA THERAPEUTICS, INC.
490 Arsenal Way
Suite 100B
Watertown, Massachusetts 02472, US
Inventors
WEILER, Sven
c/o Basilea Pharmaceutica International AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, CH
GAUCHER, Bérangère
Basilea Pharmaceutica International AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, CH
RICHALET, Florian
Basilea Pharmaceutica International AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, CH
RADIMERSKI, Thomas
c/o Basilea Pharmaceutica International AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, CH
ALOIA, Andrea
Basilea Pharmaceutica International AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, CH
Priority Data
21204520.7
25.10.2021
EP
22167146.4
07.04.2022
EP
22186200.6
21.07.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2912 | |
| EPO | Filing, Examination | 14922 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 15810 |
Total: 34873 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides compounds of formula (I) (I)and pharmaceutically acceptable salts thereof; whereinRa and Rb are both -CH3 or Ra and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2-bridging moiety;A is -CH2- or -C(=O)-;T is -N(R11)-, -N(R11)-C(=O)-, -N(R11)-S(O2)-, -O-, -C(R12)(R13)-, -C=C(R12)2, -S-, -S(O)-, -S(O2)-, -S(O2)-N(R14)- or -C(=O)-N(R14)-;and wherein R1, R2, R11, R12, R13 and R14 are as defined in the claims, as well as methods of using the compounds for the treatment of neoplastic diseases such as cancer.[French]
L'invention concerne des composés de formule (I), (I) et des sels pharmaceutiquement acceptables de ceux-ci; Ra et Rb étant tous les deux -CH3 ou Ra et Rb formant ensemble -CH2-CH2-CH2- ou une fraction de pontage de -CH2-CH2-CH2-CH2-; A étant -CH2- ou -C(=O)-; T étant -N(R11)-, -N(R11)-C(=O)-, -N(R11)-S(O2)-, -O-, -C(R12)(R13)-, -C=C(R12)2, -S-, -S(O)-, -S(O2)-, -S(O2)-N(R14)- ou -C(=O)-N(R14)-; et R1, R2, R11, R12, R13 et R14 étant tels que définis dans les revendications, ainsi que des procédés d'utilisation des composés pour le traitement de maladies néoplasiques telles que le cancer.